Thalassemia and Venous Thromboembolism

Overview

Journal Mediterr J Hematol Infect Dis

Specialty Infectious Diseases

Date 2011 Jun 30

PMID 21713079

Citations 14

Authors

Julien Succar

Khaled M Musallam

Ali T Taher

Affiliations

Soon will be listed here.

Abstract

Although the life expectancy of thalassemia patients has markedly improved over the last few decades, patients still suffer from many complications of this congenital disease. The presence of a high incidence of thromboembolic events, mainly in thalassemia intermedia, has led to the identification of a hypercoagulable state in these patients. In this review, the molecular and cellular mechanisms leading to hypercoagulability in thalassemia are highlighted, with a special focus on thalassemia intermedia being the group with the highest incidence of thrombotic events as compared to other types of thalassemia. Clinical experience and available clues on optimal management are also discussed.

Citing Articles

A Compact Differential Dynamic Microscopy-based Device (cDDM): An Approach Tool for Early Detection of Hypercoagulable State in Transfusion-Dependent-β-Thalassemia Patients.

Petiwathayakorn T, Paradee N, Hantrakool S, Jarujareet U, Intharah T, Srichairatanakool S ACS Appl Bio Mater. 2024; 7(7):4710-4724.

PMID: 38920024 PMC: 11253095. DOI: 10.1021/acsabm.4c00516.

Aortic elasticity changes in thalassemia due to heart and liver iron deposition.

Noori N, Teimouri A Caspian J Intern Med. 2023; 14(3):460-469.

PMID: 37520866 PMC: 10379797.

The clinical characteristics of acute cerebral infarction patients with thalassemia in a tropic area in China.

Liu L, Ben X, Li C, Liu J, Ma L, Liao X Transl Neurosci. 2023; 14(1):20220290.

PMID: 37362622 PMC: 10290278. DOI: 10.1515/tnsci-2022-0290.

Protein C and S levels in patients with Thalassemia intermedia.

Mohammed N J Med Life. 2022; 15(11):1415-1418.

PMID: 36567848 PMC: 9762369. DOI: 10.25122/jml-2021-0316.

Vascular Brain Damage in Thalassemia Syndrome: An Emerging Challenge.

Hashemieh M, Jafari N Iran J Child Neurol. 2022; 16(1):19-29.

PMID: 35222654 PMC: 8753003. DOI: 10.22037/ijcn.v16i3.33794.

References

Borgna Pignatti C, Carnelli V, Caruso V, Dore F, De Mattia D, Di Palma A . Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol. 1998; 99(2):76-9. DOI: 10.1159/000040814. View

Cappellini M, Motta I, Musallam K, Taher A . Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci. 2010; 1202:231-6. DOI: 10.1111/j.1749-6632.2010.05548.x. View

Eldor A, Krausz Y, ATLAN H, Snyder D, Goldfarb A, Rachmilewitz E . Platelet survival in patients with beta-thalassemia. Am J Hematol. 1989; 32(2):94-9. DOI: 10.1002/ajh.2830320204. View

Chen S, Eldor A, Barshtein G, Zhang S, Goldfarb A, RACHMILEWITZ E . Enhanced aggregability of red blood cells of beta-thalassemia major patients. Am J Physiol. 1996; 270(6 Pt 2):H1951-6. DOI: 10.1152/ajpheart.1996.270.6.H1951. View

Taher A, Otrock Z, Uthman I, Cappellini M . Thalassemia and hypercoagulability. Blood Rev. 2008; 22(5):283-92. DOI: 10.1016/j.blre.2008.04.001. View

Kuypers F, de Jong K . The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol (Noisy-le-grand). 2004; 50(2):147-58. View

Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini M . Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes. Br J Haematol. 2001; 112(1):48-50. DOI: 10.1046/j.1365-2141.2001.02482.x. View

Taher A, Musallam K, Karimi M, El-Beshlawy A, Belhoul K, Daar S . Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2009; 115(10):1886-92. DOI: 10.1182/blood-2009-09-243154. View

Winichagoon P, Fucharoen S, Wasi P . Increased circulating platelet aggregates in thalassaemia. Southeast Asian J Trop Med Public Health. 1981; 12(4):556-60. View

10.

Taher A, Musallam K, El-Beshlawy A, Karimi M, Daar S, Belhoul K . Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol. 2010; 150(4):486-9. DOI: 10.1111/j.1365-2141.2010.08220.x. View

11.

Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G . PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients. Br J Haematol. 1993; 84(1):111-7. DOI: 10.1111/j.1365-2141.1993.tb03033.x. View

12.

Taher A, Musallam K, Karimi M, El-Beshlawy A, Belhoul K, Daar S . Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010; 8(10):2152-8. DOI: 10.1111/j.1538-7836.2010.03940.x. View

13.

Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet J, Taher A . Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica. 2008; 93(6):941-2. DOI: 10.3324/haematol.12460. View

14.

Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz E . In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol. 1997; 98(1):51-6. DOI: 10.1046/j.1365-2141.1997.1502965.x. View

15.

Zurlo M, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C . Survival and causes of death in thalassaemia major. Lancet. 1989; 2(8653):27-30. DOI: 10.1016/s0140-6736(89)90264-x. View

16.

Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G . Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. Br J Haematol. 1999; 106(1):178-81. DOI: 10.1046/j.1365-2141.1999.01489.x. View

17.

Atichartakarn V, Angchaisuksiri P, Aryurachai K, Onpun S, Chuncharunee S, Thakkinstian A . Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br J Haematol. 2002; 118(3):893-8. DOI: 10.1046/j.1365-2141.2002.03711.x. View

18.

Butthep P, Bunyaratvej A, Funahara Y, Kitaguchi H, Fucharoen S, Sato S . Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study. Southeast Asian J Trop Med Public Health. 1997; 28 Suppl 3:141-148A. View

19.

Barenholz Y, Rachmilewitz E, Eldor A . Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol. 1993; 44(1):63-5. DOI: 10.1002/ajh.2830440114. View

20.

Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini M, Del Vecchio G . Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89(10):1187-93. View